Liquidia (NASDAQ:LQDA) Upgraded at BTIG Research

Liquidia (NASDAQ:LQDA) was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The brokerage currently has a $70.00 price objective on the stock. BTIG Research’s target price indicates a potential upside of 161.10% from the stock’s current price.

A number of other research firms have also recently commented on LQDA. Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Zacks Research lowered Liquidia from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 22nd. Royal Bank Of Canada set a $130.00 target price on Liquidia in a research note on Friday, July 24th. Wells Fargo & Company restated an “equal weight” rating and issued a $30.00 target price (down from $108.00) on shares of Liquidia in a research report on Friday, October 2nd. Finally, Raymond James Financial restated an “outperform” rating on shares of Liquidia in a research report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $79.46.

Liquidia Stock Performance

NASDAQ:LQDA opened at $26.81 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of 19.57 and a beta of 0.61. The company’s 50-day moving average is $63.40 and its two-hundred day moving average is $61.76. Liquidia has a 1-year low of $21.94 and a 1-year high of $93.61.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same period last year, the company earned ($0.49) EPS. Analysts forecast that Liquidia will post 2.05 EPS for the current year.

Insider Transactions at Liquidia

In related news, insider Rajeev Saggar sold 50,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the completion of the transaction, the insider owned 142,265 shares of the company’s stock, valued at approximately $10,536,145.90. This trade represents a 26.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jason Adair sold 73,631 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $69.09, for a total transaction of $5,087,165.79. Following the transaction, the insider directly owned 174,606 shares of the company’s stock, valued at $12,063,528.54. The trade was a 29.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 745,194 shares of company stock worth $41,081,702. 25.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quantinno Capital Management LP boosted its stake in shares of Liquidia by 3.6% during the 1st quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock worth $648,000 after acquiring an additional 589 shares in the last quarter. Arizona State Retirement System increased its stake in Liquidia by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after purchasing an additional 900 shares in the last quarter. Swiss National Bank increased its stake in Liquidia by 1.3% in the 1st quarter. Swiss National Bank now owns 120,400 shares of the company’s stock valued at $4,544,000 after purchasing an additional 1,600 shares in the last quarter. Valmark Advisers Inc. increased its stake in Liquidia by 10.2% in the 1st quarter. Valmark Advisers Inc. now owns 20,546 shares of the company’s stock valued at $775,000 after purchasing an additional 1,905 shares in the last quarter. Finally, Globeflex Capital L P purchased a new position in Liquidia in the 2nd quarter valued at approximately $175,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement resolving all six pending lawsuits with United Therapeutics. The agreement allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension, removing years of patent, antitrust and trade-secret litigation uncertainty. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA net sales reached $222.7 million, contributing to $396.1 million in cash and cash equivalents as of September 30. Management expects ongoing sales and existing cash to fund settlement obligations and planned clinical programs without new financing.
• Positive Sentiment: Liquidia plans to focus on expanding YUTREPIA in PAH while continuing development of the L606 clinical program and additional potential indications.
• Neutral Sentiment: CEO Roger Jeffs, CFO Michael Kaseta and several other insiders sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were programmatic and insiders retained substantial holdings, they provide a limited standalone signal about management confidence. Liquidia insider transactions
• Negative Sentiment: The settlement requires Liquidia to pay United Therapeutics a net $380.7 million in installments during 2026 and 2027, including $175 million within 30 business days. The cash outflow could reduce financial flexibility and constrain investment, although management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: Liquidia agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label. It will also stop promoting Treprostinil Injection, narrowing potential revenue opportunities.
• Negative Sentiment: Insider activity remains heavily weighted toward sales, with 106 sales and one purchase reported over the past six months. Analysts have also recently lowered some price targets following the litigation setback, adding to investor caution.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).